Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 Diabetes

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

December 5, 2024

Primary Completion Date

October 30, 2025

Study Completion Date

October 30, 2025

Conditions
Type 2 Diabetes Mellitus (T2DM)Obesity Type 2 Diabetes Mellitus
Interventions
BIOLOGICAL

PG-102

"* Participants will receive PG-102 by subcutaneous (SC) injection.~* Other Names: MG12"

OTHER

Placebo

Participants will receive placebo by SC injection

Trial Locations (14)

Unknown

The Catholic University of KOREA, Bucheon St.Mary's Hostital, Bucheon-si

Yeungnam University Medical Center, Daegu

Daejeon Eul Ji Medical Center, Eul Ji University, Daejeon

Seoul National University Bundang Hospital, Seongnam

Kangbuk Samsung Hospital, Samsung Medical Center, Seoul

KOREA University Anam Hospital, Seoul

KOREA University Asan Hospital, Seoul

Kyung Hee University Hospital at Gangdong, Seoul

Kyung Hee University, Medical Center, Seoul

Nowon Eul Ji Medical Center, Eul Ji University, Seoul

Samsung Medical Center, Seoul

Severance Hostital, Seoul

The Catholic University of KOREA, Seoul St.Mary's Hostital, Seoul

The Catholic University of KOREA, Yeouido St.Mary's Hostital in Korea, Seoul

All Listed Sponsors
lead

ProGen. Co., Ltd.

OTHER